Audentes Therapeutics Inc

Audentes Therapeutics — Technical Presentation (May 2018)

16 slides from Audentes Therapeutics's technical presentation, May 16, 2018

  1. Slide 1: ASPIRO Phase 1/2 Gene Therapy Trial In XLMTM: Interim Safety And Efficacy Findings

    X-Linked Myotubular Myopathy (XLMTM) ASPIRO Phase 1/2 Gene Therapy Trial In XLMTM: Interim Safety And Efficacy Findings Exhibit 99.2

  2. Slide 2: Safe Harbor

    Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Com

  3. Slide 3: XLMTM: A fatal disease with no treatment options

    Significant impairment of respiratory and neuromuscular function Estimated 50% mortality by 18 months Incidence: 1 in 50K newborn males AAV8 effectively penetrates skeletal muscle Muscle tissue is otherwise reasonably healthy and exhibits no dystrophic or inflammatory change MTM1 gene encodes myotub

  4. Slide 4: ASPIRO Phase 1/2 Clinical Study

    ASPIRO Phase 1/2 Clinical Study AT132 administration Weeks 9–16 taper Inclusion Criteria Subject is male <5 yrs old, or enrolled in INCEPTUS Genetically confirmed XLMTM Requires ventilator support Key Efficacy Assessments Neuromuscular CHOP INTEND MFM-20 Bayley III Muscle biopsy Developmental milest

  5. Slide 5: ASPIRO Cohort – 1x10^14 vg/kg

    ASPIRO Cohort 1 – 1x1014 vg/kg Seven patients have been transitioned from INCEPTUS into ASPIRO Interim data as of May 12, 2018 Ventilator status at screening / baseline (hours per day): Patient 1: 12 h of BiPAP Patient 2: 22 h of invasive ventilation Patient 3: 24 h of invasive ventilation Patient 4

  6. Slide 6: Safety and Tolerability

    Safety and Tolerability Adverse Events and Laboratory Parameters

  7. Slide 7: AT132 Safety and Tolerability Profile

    AT132 Safety and Tolerability Profile at 1 x 1014 vg/kg Interim data as of May 12, 2018 No tolerability issues during study drug administration Six serious adverse events (SAEs), five in Patient 3 Patient 3 Hospitalization for pneumonia (week 2); not treatment-related; history of 8 similar events du

  8. Slide 8: Serum Enzyme Elevations in 2/6 Patients, Controlled with Treatment

    Serum Enzyme Elevations in 2/6 Patients, Controlled with Treatment Interim data as of May 12, 2018 Patient 1 Patient 2 Patient 3 Patient 5 Patient 6 Patient 7

  9. Slide 9: Neuromuscular Function: CHOP-INTEND and Developmental Milestones

    NEUROMUSCULAR FUNCTION CHOP-INTEND and Developmental Milestones

  10. Slide 10: Significant Improvements in Neuromuscular Function as Assessed by the CHOP-INTEND Scale

    Significant Improvements in Neuromuscular Function as Assessed by the CHOP-INTEND Scale Interim data as of May 12, 2018 Maximum score = 64 points (normally reached by 3-6 months of age) CHOP-INTEND score Patient # Baseline Score in ASPIRO Most recent score (Wk) Change from baseline (%) 1 29 64 (Wk 2

  11. Slide 11: Multiple Motor Developmental Milestones Achieved

    Interim data as of May 12, 2018 Multiple Motor Developmental Milestones Achieved First-year developmental milestones in healthy children Patient 1 (0.8y) Baseline Week 24 Rolling over Head Control Sitting unassisted >5 sec - - - Patient 2 (4.1y) Baseline Week 24 Baseline Week 12 Baseline Week 24 Pat

  12. Slide 12: Respiratory Function: Maximal Inspiratory Pressure and Ventilator Dependence

    RESPIRATORY FUNCTION Maximal Inspiratory Pressure and Ventilator Dependence

  13. Slide 13: Significant Improvements in Respiratory Function as Assessed by MIP

    Interim data as of May 12, 2018 Significant Improvements in Respiratory Function as Assessed by Maximal Inspiratory Pressure (MIP) Estimated normal minimal pressures in healthy children Maximum Inspiratory Pressure (cmH2O) Patient # Baseline Pressure in ASPIRO Most recent Pressure (Wk) Change from b

  14. Slide 14: Ventilator Dependence Within the Previous Hours

    Ventilator Dependence Within the Previous 24 Hours First treated patient has reached ventilator independence Interim data as of May 12, 2018 INCEPTUS Visits ASPIRO Visits Patient 1 Patient 2 Patient 3 Patient 4 (Ctrl) Patient 5 Patient 6 Patient 7

  15. Slide 15: Summary

    AUDENTES > SUMMARY Courageous Patients. Bold Effort.

  16. Slide 16: ASPIRO Key Findings and Program Next Steps

    ASPIRO Key Findings and Program Next Steps Well tolerated during administration and manageable safety profile to date Significant improvements in neuromuscular and respiratory function at 24-week timepoint Encouraging initial efficacy results observed at the four-week timepoint in Cohort 1 expansion

Audentes Therapeutics — Technical Presentation (May 2018) on 6ix